

GENE GUT

Using RNA therapy to treat
ileal Crohn's Disease



@GENEGUT_EU

An innovative EU-funded research project to change the treatment paradigm for Crohn's Disease patients with a new RNA-based advanced therapy.

For patients, at the forefront of research

Following a patient-centred approach, GENEGUT aims to develop the first oral RNA-based therapy for ileal Crohn's Disease, tackling inflammation locally in the intestinal tissue, while avoiding systemic side effects.

GENEGUT is a four year Research and Innovation Action funded with 5.4 million Euro by the European Union's Horizon Europe programme and is coordinated by the University College Cork, Ireland.



Learn more on www.genegut.eu



Funded by the European Union (GA 101057491) and supported the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 22.00119. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.



UK participants in Horizon Europe Project GENEGUT are supported by UKRI grant number 10042451 (Bangor University).